论文部分内容阅读
一、抗胸腺细胞血清(ATG)、抗淋巴细胞血清(ALG)对再生障碍性贫血的治疗效果法国Mathe等最先报道了对重症再生障碍性贫血采用ATG、ALG治疗的效果。他们于1970年观察到应用ALG后进行骨髓移植治疗的患者,尽管骨髓移植没有成功,但患者自身的骨髓机能却得到恢复。所以,推测ALG可能有使再生障碍性贫血患者骨髓功能恢复的作用。直到七十年代后半期,体外实验报告中相继提示以T淋巴细胞为主的免疫学机制与再生障碍性贫血患者的骨髓造血干细胞损害有关。在临床方面也弄清了对一卵双生儿之间进
First, anti-thymocyte serum (ATG), anti-lymphocyte serum (ALG) treatment of aplastic anemia French Mathe first reported the use of ATG, ALG treatment of severe aplastic anemia. In 1970, they observed that patients who underwent bone marrow transplantation after applying ALG had their own bone marrow function recovered, despite the failure of bone marrow transplantation. Therefore, it is hypothesized that ALG may have a role in restoring bone marrow function in patients with aplastic anemia. Until the second half of the seventies, in vitro experiments have been reported in the T lymphocyte-based immunological mechanisms and aplastic anemia in patients with bone marrow hematopoietic stem cell damage. In the clinical area also made clear between the twins into a egg